addition to
board of directors
Novocure has elected Timothy J. Scannell, President and Chief Operating Officer of Stryker Corporation, to our board of directors.
Learn more
financial
update
Novocure announced fourth quarter and full year 2020 preliminary net revenues and provided a company update.
Learn more
first patient enrolled
in TRIDENT
The first patient has been enrolled in our global phase 3 TRIDENT trial in newly diagnosed glioblastoma.
Learn more
national reimbursement
in Switzerland
We received national reimbursement in Switzerland for our cancer therapy in combination with temozolomide for the treatment of newly diagnosed glioblastoma.
Learn more
a strategic
alliance
Novocure and the NYU Grossman School of Medicine’s Department of Radiation Oncology entered into a strategic alliance that provides a framework for preclinical and clinical development projects studying Tumor Treating Fields.
Learn more
the story
of Novocure
In 2000, our founder Professor Yoram Palti sought to leverage his expertise in biophysics to develop a new way to treat cancer that would destroy tumor cells while sparing healthy tissue and avoiding many of the life-altering side effects of existing cancer therapies. Novocure has grown into an international oncology company with nearly 600 employees and operations in the U.S., Europe and Asia.
Learn More
we can leverage physics to fight cancer
Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and potentially causing cancer cells to die.
OUR THERAPY
explore our clinical pipeline
Our research shows that Tumor Treating Fields have an antimitotic effect in more than 18 solid tumor types in culture and in eight in vivo tumor models.
OUR PIPELINE
we are dedicated to improving the lives of cancer patients
Patients remain at the heart of the work we do every day. Learn more about our patients, their families and the people working to deliver patient-forward therapies to treat cancer.
PATIENT-FORWARD